Loading patent…
OwnerMarie-Lise GOUGEON, Manuelle VIGUIER +2inventors
InventorsMarie-Lise GOUGEON, Manuelle VIGUIER, Nicolas FAZILLEAU, Herve BACHELEZ
Estimating the term…
The present invention relates to Lichen planus (LP), and more specifically to no erosive form of LP (NELP). The invention provides an immune signature for LP, which is not found in other cutaneomucosal chronic inflammatory diseases. The invention moreover provides different diagnosis methods and methods of treating NELP, based on this immune signature. The inventors have indeed demonstrated the presence of HPV16-specific activated CTL in blood and lesion samples corresponding to the different clinical forms of LP, not only in erosive oral LP, while a different scenario operates in other cutaneomucosal chronic inflammatory diseases. This HPV16-specific activated CTL is characterized by TCRVβ3+ CD8+ T-cells oligoclonal expansions.
A method for detecting the presence of an immune response against a human papilloma virus infection in a biological sample of a patient suspected to have non-erosive lichen planus (NELP), said method comprising:
A method for detecting the presence of a clonal expansion of CD8+ T cells in a biological sample of a patient suspected to have a lichen sclerosus et atrophicus (LSA), said method comprising:
A method for detecting an HPV infection in a patient suspected to have non-erosive lichen planus (NELP) comprising providing a non-mucosal cell sample from the patient, contacting the non-mucosal sample with at least one HPV peptide, and detecting the interaction between the HPV peptide and cells in the sample.
A method for diagnosing in a patient an LP, preferably an LP clinical form other than the erosive oral form of LP, comprising detecting TCRVβ3+ CD8+ T-cells oligoclonal expansion in a sample of the peripheral blood or of a lesion of the patient to be diagnosed.
A method for diagnosing in a patient an LP, preferably an LP clinical form other than the erosive oral form of LP, comprising detecting a predominant usage of the TCRVβ3 gene segment in a sample of circulating CD8+ T cells of the patient with respect to the same usage in circulating CD4+ T-cells counterparts.
A method for diagnosing in a patient an LP, preferably an LP clinical form other than the erosive oral form of LP, comprising detecting oligoclonal CD8+ T cells specific for HPV16, preferably CD8+ Vβ3+ T cells specific for HPV16, in a blood sample of the patient, and/or in a sample from LP lesions of the patient.
A kit comprising:
The kit according to any one of claims 26 to 31, further comprising a dextramer-HPV16.
A method for treating a patient suffering from a LP, preferably an LP clinical form other than the erosive oral form of LP, comprising the steps of:
A method for monitoring treatment of an LP patient, comprising determining in a biological sample obtained from said patient, the usage of the TCRVβ3 gene segment in circulating CD8+ T cells, before and after treatment, and detecting a modulation or absence of modulation of the TCRVβ3 gene segment usage, preferably a decrease of said usage.
A method for monitoring treatment of an LP patient, comprising assaying oligoclonal CD8+ T cells specific for HPV16 in a biological sample obtained from the patient, before and after treatment, and detecting a decrease of the number of CD8+ T cells specific for HPV16, preferably of the number of CD8+ Vβ3+ T cells specific for HPV16.
Dependencies are inferred from the claim text.